Azadyne is a biotech spin-out company from Trinity College Dublin founded by Professors Stephen Connon, Vincent Kelly, Mike Southern and CEO, Dr. Jason Rutt, ex head of UK patents, Pfizer. The company is dedicated to delivering improved medicines for patients with autoimmune disease, including Multiple Sclerosis. Its approach is based on the strategic design of derivatives of a natural micronutrient.
Health Care, Pharmaceutical, Biotechnology
Between €1 million-€ 2.5 million
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as Azadyne? We’re happy to assist you with our Startup Sourcing service.